Nothing Special   »   [go: up one dir, main page]

HUE026386T2 - Tumorszelektív adenovírus E1A és E1B mutánsai - Google Patents

Tumorszelektív adenovírus E1A és E1B mutánsai Download PDF

Info

Publication number
HUE026386T2
HUE026386T2 HUE10749205A HUE10749205A HUE026386T2 HU E026386 T2 HUE026386 T2 HU E026386T2 HU E10749205 A HUE10749205 A HU E10749205A HU E10749205 A HUE10749205 A HU E10749205A HU E026386 T2 HUE026386 T2 HU E026386T2
Authority
HU
Hungary
Prior art keywords
expression
cells
pea3
deletion
tumor
Prior art date
Application number
HUE10749205A
Other languages
English (en)
Inventor
Tony Reid
Farah Hedjran
Shantanu Kumar
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HUE026386T2 publication Critical patent/HUE026386T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (6)

1. (îyôgyas^l ^s?îiJÎS^iy, &amp;mé|ÿ tártalrmiz egy gyégyássítslsg «Mogarlhstö kötÖ&amp;ipigöt U egy mkmàÈtèm: sésm^^ 'Φ&amp; s» adsitevlraz tartalmaz egy módosított Els szabályozó székeseiét, aboi legalább egy kötőhely v$0 <$pek :«|jf êwkâmiÊ&amp; fóstdote törölve vast, ahol &amp; legalább egy Pea3 kötőhely: iinkelösálls: rés^ëts g kötÄlpek s;« s részlete, amely törlés «setén esökkentl a kötőhely Pea3-hoz való: kötődési ablnilását
2. Az l. igérs>|töOí szisriau gyógyászati któtsaásy, tdsol s -303. ismazámtlli a -141. serszátmg terjedő tartományba». legalább egy nukleolíd megmarad.
3. Az 1, vagy a 2. igéoypost szériát! gyógyászati készítmény, ahol aPetű II leal! HI, Pead IV és s P«a3 V. vagy enteis egy imhsiöeálís rt&amp;zlet® közül legalább «gy törölve van, ahol tetszőlegesen Μág b) Is c) pontok ,|W választott tátiy törölve vas: á) a Pe&amp;3 0 és Pea3 01, vagy meteask egy íazkeiomdis részlete kW legalább «gyi; b> Pesd IX vagy esések egy íuakekssáiis részlete és Pes3 Hl vstgy opdk.. «gy &amp;«!potíál!s résiste? és c} a Pea3 I V és Pez3 V, vagy ezeknek egy Aaötskstálh resztet« közöllegalábfei egy,
4. A» l.*3, í$éBy$mtá&amp;bármelyike szerinti pőgytasí Mszttínény, ®M *Pead 1 v^gymmk egy iktskekmálts részlete msgmar&amp;d, ahol tetszőlegese» legalább egy E2F kötőhely vagyssnek egy ftmkektstálls részlete megmarad, :INól ©mpk a legalább egy B2F kötőhelynek &amp; ibnkshmáif s üzlete a kötőhelynek «&amp;» résiste, zmsiyi: t&amp;Ä esÄtsÄtoittl a kötőhely B2f~|sz való kötődési affinitását.
5. M1. igéoypoai szériák gyégyámtti késitmény, «kel m múkm rekombieáns adesKmms mdäsoti# dsleelókai tartalmaz az 11® inidádős helyet megelőző szakaszban (tpmsmöh ahol a törlés a íövtAszök feösil választom (a) a -393. sorszámtól a ~3Ö4. sorszámig terjedő sukleoíldok; (b) a -305. sorszámtól »-25S- sorszámig terjedő rntkleráldok; (c) a -220. sotszámtól a -240. sorszámig terjedő nukleotidoh; |á) s 299. sorssánriét a. -293- sotaZâmlg tér|edö naklsotidok;; fb) a --370. sorszámé a -20$, sobs^tbtg terjedő nnkieotláö&amp;ök:; (Ö a -299. sormÉmtői a -293. somzárnlg tspdő eukleetM és a-290-2öS-ös sorszámitmkleothi
6. Az ! -S. ígéáyí»otrÉ bármelyike szedni* gyógyászati készítmény a rák kezelésében. t# M^ztszMmá. 3. A 6. igénypont szedni! féihasználáffi gyégyászsb készíttsézy, áltól a gyógyászati készitmétty a cblsejttel kerül ésiotkezésbe. §, Μ nm Xߣ4mt agy pepid célsejtbe« való ssslelaív expasÂàaât^ as&amp;ety péipex ifte« $te$Ust èm&amp;mèshe hassak egy setesbbp&amp;s ^sj^vfeassa!, aki m #femv$m tarplpxas «gy »kisböd E1 a szsbél>%aé «zekveaetSt, ahol legalább 's&amp;$*ss&amp; fcbtáheíy mgy törölve vas* stó alegalÄ Fsai köröhsly «*»ly:'Ä^*sÄ esékkettti s kötőhely Pekkte, vaié kötődd affinitását, Us, hogy a médsaer asm az emberi vagy Misii test b|äÄsai erödszsre. ív A 7, vagy 8. igényperé iáfgya. aboi &amp; rekombkitis vírus delédós matáas El a szabályozd szekveseik isttalrntts, amely méksMékipesen kapesejödlk egy pepidet kódold Rükfcsíkbzekvaííciábyz, li. A Ä igfeypootak bfesdyskéP liegya, aboi a célsejt egy permit Ä közül választott Ä MÄ igénygse&amp;tok öirmclytkisiek krgya5 abo! ax emHtxAmkombikms viba selektiven expröággál egy ils isofemot eèôî ex lia myhrmâMéaW xzekveoeia mÄÄ^sasl^ekbibdik m pédeskoti Bla szabályozd aeekveíiciátsoz. 13 < A H. igényperé tárgya. aboi a reketnbbsàtïs xderKeims sxelekiivee expresszáija ax Ela-].2S-i vagy az E1S13SA :Î3< Αχ előzd ígényporéok bármelyífcérisk tárgya, aboi a. ívkömblnáns adenovlres ié«yegdbsî! kkásya ttz Bla izelotpek ekjvessxiöját, sitôt ex Bîa itznlbtmet kkMö sxvkvbti« míSköéékápssan kapesoiédik m emïitmt módosított EU szaMlyoxo spkvesetâhox 14 A VI %œypiai iiárgya, abt>l s Sda&amp;t Bla izeforts az EjadES vagy sa E1&amp;- 13$. il. Ax etéxd igeeyponiök bármelyikének tÉfySj ibol a rekoMnesps ádenovíras tavibbá tsstslmax még egy olyas I>NS-sxakv«se4ál; ami sa Elb^lllCí|bsgeíci6s helyre van beilleszive, 14 A ll.tgásypesrt tárgya, a&amp;bl az Essxssviós báty aa Elb-lbk, aisfíbélye és azB'lb»55K. saartbeiye köxött helyezkedik el. t%- A13. vágy lé, îgèi|fMî'^y%:W«z Bíb«l^i^^i#s j^y lamteaxa 202 házs^ie$S$iójátiBE Elb-tOK stsriMpétia. Il A 15-12, igénypontok bsrmsiy&amp;ének tárgya. akd a EtkS-szekvessela agy tmaor aakxéxss Äoxt vagy «msek agy lEnkcioxsélis részletét ködeié szekvencia. 14. A 1.4 Ti. igénypontok bfeeiyikének tárgys, silói a I>bl$ *$zek vcock egy K RAS-t vagy ennek «gy faakéibsáUs részletét kidőld ^ekveogla.
HUE10749205A 2009-03-02 2010-03-02 Tumorszelektív adenovírus E1A és E1B mutánsai HUE026386T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15682209P 2009-03-02 2009-03-02

Publications (1)

Publication Number Publication Date
HUE026386T2 true HUE026386T2 (hu) 2016-06-28

Family

ID=42710189

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE10749205A HUE026386T2 (hu) 2009-03-02 2010-03-02 Tumorszelektív adenovírus E1A és E1B mutánsai
HUE15182086A HUE046565T2 (hu) 2009-03-02 2010-03-02 Tumorszelektív adenovírus E1A és E1B mutánsok

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15182086A HUE046565T2 (hu) 2009-03-02 2010-03-02 Tumorszelektív adenovírus E1A és E1B mutánsok

Country Status (15)

Country Link
US (5) US9073980B2 (hu)
EP (4) EP2403951B1 (hu)
JP (5) JP6072414B2 (hu)
KR (4) KR102150027B1 (hu)
CY (1) CY1122385T1 (hu)
DK (2) DK2403951T3 (hu)
ES (2) ES2750305T3 (hu)
HR (2) HRP20151396T1 (hu)
HU (2) HUE026386T2 (hu)
LT (1) LT3029144T (hu)
PL (2) PL2403951T3 (hu)
PT (2) PT3029144T (hu)
SI (2) SI2403951T1 (hu)
SM (1) SMT201500329B (hu)
WO (1) WO2010101921A2 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2403951B1 (en) 2009-03-02 2015-09-30 The Regents of The University of California Tumor-selective adenovirus e1a and e1b mutants
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
CA3013639A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN118307682A (zh) 2016-09-27 2024-07-09 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
AU2018212017A1 (en) * 2017-01-30 2019-08-15 Epicentrx, Inc. Tumor selective TATA -box and CAAT-box mutants
KR20190128634A (ko) * 2017-01-30 2019-11-18 에피센트알엑스, 인코포레이티드 다중 트랜스진 재조합 아데노바이러스
EP3610003A4 (en) * 2017-04-10 2021-01-06 EpicentRx, Inc. RECOMBINANT VIRUS PRODUCTION PROCESS
EA201990822A1 (ru) * 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
US20200155625A1 (en) * 2017-05-24 2020-05-21 Epicentrx, Inc. Anti-angiogenic adenovirus
CA3064863A1 (en) * 2017-05-26 2018-11-29 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
US11834492B2 (en) 2017-09-27 2023-12-05 Epicentrx, Inc. Human IL-10 receptor alpha fusion proteins
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
WO2019191494A1 (en) * 2018-03-28 2019-10-03 Epicentrx, Inc. Personalized cancer vaccines
CN113015806A (zh) * 2018-08-31 2021-06-22 奥尔卡治疗有限公司 包含糖原合酶激酶-3(gsk3)编码区的重组的具有复制能力的病毒和杀伤异常细胞的方法
CA3154115A1 (en) 2019-10-08 2021-04-15 Yunan ZHENG Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4114449A2 (en) 2020-03-05 2023-01-11 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
CN114262691A (zh) * 2020-09-16 2022-04-01 杭州康万达医药科技有限公司 分离的能够用于表达外源基因的溶瘤腺病毒、载体、治疗剂及其用途
WO2024015876A1 (en) 2022-07-13 2024-01-18 Epicentrx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643567A (en) 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5352775A (en) 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
EP0659209A1 (en) 1991-07-26 1995-06-28 The University Of Rochester Cancer therapy utilizing malignant cells
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
DE69433461T2 (de) 1993-09-15 2004-11-18 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanter Alphavirus Vektor
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US5902925A (en) 1996-07-01 1999-05-11 Integrated Sensor Solutions System and method for high accuracy calibration of a sensor for offset and sensitivity variation with temperature
GB9626029D0 (en) 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
US20050287120A1 (en) * 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
EP1135514B1 (en) * 1999-01-28 2009-05-13 Onyx Pharmaceuticals, Inc. E1b-deleted adenoviral shuttle vectors
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
AU2001257611A1 (en) * 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
US6884613B2 (en) * 2000-08-25 2005-04-26 The General Hospital Corporation Selective precipitation of viruses
CN1183250C (zh) 2000-12-01 2005-01-05 卫健生物科技有限公司 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法
GB0117198D0 (en) * 2001-07-13 2001-09-05 Btg Int Ltd Anti-neoplastic viral agents
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
WO2004020971A2 (en) * 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20060270016A1 (en) * 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
CA2610360A1 (en) * 2004-12-31 2006-07-06 Per Sonne Holm E1-minus adenoviruses and use thereof
US20100137415A1 (en) 2007-04-20 2010-06-03 Takara Bio Inc. Vector for gene therapy
EP2403951B1 (en) 2009-03-02 2015-09-30 The Regents of The University of California Tumor-selective adenovirus e1a and e1b mutants

Also Published As

Publication number Publication date
KR20170077278A (ko) 2017-07-05
PT2403951E (pt) 2016-01-29
EP3029144B1 (en) 2019-07-10
LT3029144T (lt) 2019-10-25
ES2557812T3 (es) 2016-01-28
KR20110122866A (ko) 2011-11-11
EP2403951A4 (en) 2012-08-22
KR102020018B1 (ko) 2019-09-09
PL3029144T3 (pl) 2020-06-01
PT3029144T (pt) 2019-10-28
SI2403951T1 (sl) 2016-04-29
JP6375273B2 (ja) 2018-08-15
US20210171917A1 (en) 2021-06-10
KR20190104643A (ko) 2019-09-10
PL2403951T3 (pl) 2016-04-29
JP6072414B2 (ja) 2017-02-01
WO2010101921A3 (en) 2011-01-06
US10876097B2 (en) 2020-12-29
US9073980B2 (en) 2015-07-07
EP3591059B1 (en) 2022-07-20
EP2403951A2 (en) 2012-01-11
KR102150027B1 (ko) 2020-10-26
JP2022023074A (ja) 2022-02-07
US20190136204A1 (en) 2019-05-09
CY1122385T1 (el) 2021-01-27
SMT201500329B (it) 2016-02-25
KR101922539B1 (ko) 2018-11-27
JP2016028035A (ja) 2016-02-25
HRP20151396T1 (hr) 2016-03-25
HUE046565T2 (hu) 2020-03-30
US11618888B2 (en) 2023-04-04
EP3029144A1 (en) 2016-06-08
DK2403951T3 (en) 2016-01-11
KR20180049188A (ko) 2018-05-10
HRP20191808T1 (hr) 2019-12-27
JP2012519014A (ja) 2012-08-23
JP6817979B2 (ja) 2021-01-20
DK3029144T3 (da) 2019-10-21
WO2010101921A2 (en) 2010-09-10
EP4123030A1 (en) 2023-01-25
ES2750305T3 (es) 2020-03-25
US20110318311A1 (en) 2011-12-29
JP2020078326A (ja) 2020-05-28
EP3591059A1 (en) 2020-01-08
SI3029144T1 (sl) 2019-11-29
KR101752910B1 (ko) 2017-06-30
EP2403951B1 (en) 2015-09-30
US20160017294A1 (en) 2016-01-21
US20230272349A1 (en) 2023-08-31
JP7326396B2 (ja) 2023-08-15
JP2018113971A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
US11618888B2 (en) Tumor-selective E1A and E1B mutants
US10538744B2 (en) Use of adenovirus and nucleic acids coding therefor
CA2836987C (en) Chimeric adenoviruses for use in cancer treatment
JP6388593B2 (ja) Ｅ１ｂタンパク質の１５６ｒスプライシングアイソフォームの割合を増加させた腫瘍溶解性アデノウイルス
US8951772B2 (en) Adenoviruses, nucleic acids coding therefor, and use thereof
JP2004535768A (ja) アデノウィルスシステム及びその使用